1. GPCR/G Protein
    Neuronal Signaling
  2. Opioid Receptor

ADL-5859 

Cat. No.: HY-13044 Purity: 98.81%
Data Sheet SDS Handling Instructions

ADL5859 is a δ-opioid receptor agonist with Ki of 0.8 nM, selectivity against opioid receptor κ, μ, and weak inhibitory activity at the hERG channel.

For research use only. We do not sell to patients.
ADL-5859 Chemical Structure

ADL-5859 Chemical Structure

CAS No. : 850173-95-4

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $145 In-stock
5 mg $132 In-stock
10 mg $220 In-stock
50 mg $770 In-stock
100 mg $1260 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

    ADL-5859 purchased from MCE. Usage Cited in: Eur J Pharmacol. 2016 Jun 15;781:53-9.

    The DOR agonist ADL5859 shows antidepressant-like effects in the FST in C57BL/6J mice.
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References

    Description

    ADL5859 is a δ-opioid receptor agonist with Ki of 0.8 nM, selectivity against opioid receptor κ, μ, and weak inhibitory activity at the hERG channel. IC50 value: 0.8 nM(Ki) Target: δ-opioid receptor ADL-5859 (ADL5859) is an δ-opioid receptor agonist (Ki=0.84 nM, EC50=20 nM). ADL-5859 (ADL5859) is an agonist agent that selectively stimulates the δ-opioid receptor with potential application in a wide range of inflammatory, neuropathic and acute pain conditions. In addition, Delta agonists are thought to modulate other biological processes that may manifest themselves in disease states or conditions such as overactive bladder and depression.ADL-5859 (ADL5859) is useful for inflammatory, neuropathic and acute pain conditions.

    Clinical Trial
    NCT Number Sponsor Condition Start Date Phase
    NCT00603265 Cubist Pharmaceuticals LLC Peripheral Neuropathy|Neuropathic Pain November 2007 Phase 2
    NCT00626275 Cubist Pharmaceuticals LLC Rheumatoid Arthritis October 2007 Phase 2
    NCT00979953 Cubist Pharmaceuticals LLC|Pfizer Osteoarthritis of the Knee October 2009 Phase 2
    NCT00993863 Cubist Pharmaceuticals LLC Acute Pain June 2007 Phase 2
    NCT00603265 Cubist Pharmaceuticals LLC Peripheral Neuropathy|Neuropathic Pain November 2007 Phase 2
    NCT00626275 Cubist Pharmaceuticals LLC Rheumatoid Arthritis October 2007 Phase 2
    NCT00979953 Cubist Pharmaceuticals LLC|Pfizer Osteoarthritis of the Knee October 2009 Phase 2
    NCT00993863 Cubist Pharmaceuticals LLC Acute Pain June 2007 Phase 2
    View MoreCollapse
    References
    Molecular Weight

    428.95

    Formula

    C₂₄H₂₉ClN₂O₃

    CAS No.

    850173-95-4

    Storage
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    Shipping

    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    10 mM in DMSO

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number

     

    Organization name *

    Country *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    ADL-5859
    Cat. No.:
    HY-13044
    Quantity: